{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:49:28Z","timestamp":1782722968420,"version":"3.54.5"},"reference-count":115,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY21H020001"],"award-info":[{"award-number":["LY21H020001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LHDMZ24H020001"],"award-info":[{"award-number":["LHDMZ24H020001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870255"],"award-info":[{"award-number":["81870255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300347"],"award-info":[{"award-number":["82300347"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.hrthm.2025.12.019","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:10:35Z","timestamp":1765818635000},"page":"e1212-e1222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolite-centric perspectives on QT prolongation: Molecular mechanisms and clinical implications beyond the parent drug"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5166-2528","authenticated-orcid":false,"given":"Zequn","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangfang","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2025.12.019_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200225040-00004","article-title":"Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview","volume":"25","author":"De Ponti","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.hrthm.2025.12.019_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrd1108","article-title":"The impact of drug-induced QT interval prolongation on drug discovery and development","volume":"2","author":"Fermini","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hrthm.2025.12.019_bib3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1067\/mcp.2000.106127","article-title":"Mechanism of cardiotoxicity of halofantrine","volume":"67","author":"Wesche","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0008-6363(02)00448-0","article-title":"The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels","volume":"55","author":"Mbai","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2025.12.019_bib5","first-page":"143","article-title":"[Projection of new antihistamines]","volume":"28","author":"Eseverri","year":"2000","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.hrthm.2025.12.019_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2165\/00003495-200059040-00018","article-title":"Ebastine: an update of its use in allergic disorders","volume":"59","author":"Hurst","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.hrthm.2025.12.019_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00003495-200059020-00020","article-title":"Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria","volume":"59","author":"Simpson","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.hrthm.2025.12.019_bib8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1211\/jpp.60.11.0012","article-title":"Cyamemazine metabolites: effects on human cardiac ion channels in-vitro and on the QTc interval in guinea pigs","volume":"60","author":"Crumb","year":"2008","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bjp.0706892","article-title":"Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine","volume":"149","author":"Rajamani","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s11095-006-0070-7","article-title":"Effects of antipsychotic drugs on I(to), I (Na), I (sus) (K1), and hERG: QT prolongation, structure activity relationship, and network analysis","volume":"23","author":"Crumb","year":"2006","journal-title":"Pharm Res"},{"key":"10.1016\/j.hrthm.2025.12.019_bib11","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/17425255.2010.531259","article-title":"Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion","volume":"6","author":"Citrome","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/bdd.490","article-title":"Myocardium distribution of sertindole and its metabolite dehydrosertindole in guinea-pigs","volume":"27","author":"Canal-Raffin","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.hrthm.2025.12.019_bib13","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1161\/CIRCRESAHA.113.301971","article-title":"Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening","volume":"113","author":"Moreno","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.hrthm.2025.12.019_bib14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.hrthm.2016.02.003","article-title":"Mechanisms of acquired long QT syndrome in patients with propionic academia","volume":"13","author":"Bodi","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.12.019_bib15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/jcph.1563","article-title":"Progesterone metabolites inhibit the human ether-a-go-go-related gene and predict QT interval length","volume":"60","author":"Shugg","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/15376516.2018.1440679","article-title":"Arsenic induces cardiac rhythm dysfunction and acylcarnitines metabolism perturbation in rats","volume":"28","author":"Phan","year":"2018","journal-title":"Toxicol Mech Methods"},{"key":"10.1016\/j.hrthm.2025.12.019_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/tpj.2010.76","article-title":"Genome-wide association study of antipsychotic-induced QTc interval prolongation","volume":"12","author":"Aberg","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.hrthm.2025.12.019_bib18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/tpj.2014.6","article-title":"Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia","volume":"14","author":"Suzuki","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.hrthm.2025.12.019_bib19","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1360-0443.2011.03767.x","article-title":"Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy","volume":"107","author":"Roy","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.hrthm.2025.12.019_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jat\/bkw135","article-title":"Tell-tale SNPs: the role of CYP2B6 in methadone fatalities","volume":"41","author":"Ahmad","year":"2017","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jpba.2015.04.036","article-title":"A novel HPLC-MS\/MS method for the simultaneous determination of astemizole and its major metabolite in dog or monkey plasma and application to pharmacokinetics","volume":"114","author":"Back","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.hrthm.2025.12.019_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.687007","article-title":"Molecular insights into the gating kinetics of the cardiac hERG channel, illuminated by structure and molecular dynamics","volume":"12","author":"Zequn","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173813","article-title":"Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir\/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel","volume":"893","author":"Zequn","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00005344-200303000-00009","article-title":"Desbutylhalofantrine: evaluation of QT prolongation and other cardiovascular effects after intravenous administration in vivo","volume":"41","author":"McIntosh","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejphar.2003.11.003","article-title":"Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells","volume":"484","author":"Traebert","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01608-21","article-title":"Population pharmacokinetic and concentration-QTc analysis of delamanid in pediatric participants with multidrug-resistant tuberculosis","volume":"66","author":"Sasaki","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.hrthm.2025.12.019_bib27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/cpt.2685","article-title":"Assessing prolongation of the corrected QT interval with bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens","volume":"112","author":"Tanneau","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jcph.573","article-title":"Effects of enzastaurin and its metabolites on the QT interval in cancer patients","volume":"56","author":"Welch","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1208\/s12248-021-00573-1","article-title":"Parent and metabolite concentration-QT modeling to evaluate QT-interval prolongation at savolitinib therapeutic doses","volume":"23","author":"Schalkwijk","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.hrthm.2025.12.019_bib30","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/jcph.70051","article-title":"Assessment of the effects of fruquintinib on cardiac safety in patients with metastatic colorectal cancer","volume":"65","author":"Zhou","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib31","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1177\/0960327110396528","article-title":"Effects of nortriptyline on QT prolongation: a safety pharmacology study","volume":"30","author":"Jeon","year":"2011","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib32","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.clinthera.2017.08.020","article-title":"A thorough QT\/QTc study of clobazam in healthy volunteers","volume":"39","author":"Tolbert","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bmcl.2017.12.020","article-title":"Molecular determinants of loperamide and N-desmethyl loperamide binding in the hERG cardiac K+ channel","volume":"28","author":"Vaz","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.hrthm.2025.12.019_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173532","article-title":"Norquetiapine blocks the human cardiac sodium channel Nav1.5 in a state-dependent manner","volume":"885","author":"Kim","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2009.12.006","article-title":"4-hydroxytamoxifen inhibits K(+) currents in mouse ventricular myocytes","volume":"629","author":"El Gebeily","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bjp.0706890","article-title":"Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology","volume":"149","author":"Hancox","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/toxsci\/kfw104","article-title":"Histone deacetylase inhibitors prolong cardiac repolarization through transcriptional mechanisms","volume":"153","author":"Spence","year":"2016","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.hrthm.2025.12.019_bib39","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacep.2016.02.015","article-title":"Influence of oral progesterone administration on drug-induced QT interval lengthening: a randomized, double-blind, placebo-controlled crossover study","volume":"2","author":"Tisdale","year":"2016","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib40","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1161\/CIRCULATIONAHA.107.702407","article-title":"Progesterone regulates cardiac repolarization through a nongenomic pathway: an in vitro patch-clamp and computational modeling study","volume":"116","author":"Nakamura","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.12.019_bib41","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.hrthm.2012.01.009","article-title":"Estradiol promotes sudden cardiac death in transgenic long QT type 2 rabbits while progesterone is protective","volume":"9","author":"Odening","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2025.12.019_bib42","doi-asserted-by":"crossref","first-page":"22186","DOI":"10.1074\/jbc.M110.198853","article-title":"Progesterone impairs human ether-a-go-go-related gene (HERG) trafficking by disruption of intracellular cholesterol homeostasis","volume":"286","author":"Wu","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hrthm.2025.12.019_bib43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpeds.2006.11.043","article-title":"Prolonged QTc intervals and decreased left ventricular contractility in patients with propionic acidemia","volume":"150","author":"Baumgartner","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.hrthm.2025.12.019_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107733","article-title":"Systemic primary carnitine deficiency induces severe arrhythmia due to shortening of QT interval","volume":"140","author":"Lodewyckx","year":"2023","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.hrthm.2025.12.019_bib45","doi-asserted-by":"crossref","first-page":"11853","DOI":"10.3168\/jds.2025-26474","article-title":"Lactoferrin alleviates doxorubicin-induced myocardial injury in mice: associations with gut microbiota and microbial metabolites","volume":"108","author":"Wu","year":"2025","journal-title":"J Dairy Sci"},{"key":"10.1016\/j.hrthm.2025.12.019_bib46","doi-asserted-by":"crossref","first-page":"18822","DOI":"10.1021\/acs.jafc.5c08360","article-title":"Identification of critical gut metabolites mediating the protective effects of Lacticaseibacillus paracasei on myocardial injury in mice","volume":"73","author":"Wu","year":"2025","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.hrthm.2025.12.019_bib47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1742-7843.2007.00144.x","article-title":"Angelica sinensis: a novel adjunct to prevent doxorubicin-induced chronic cardiotoxicity","volume":"101","author":"Xin","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.freeradbiomed.2016.12.005","article-title":"Non-enzymatic oxidized metabolite of DHA, 4(RS)-4- F4t - neuroprostane protects the heart against reperfusion injury","volume":"102","author":"Roy","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.hrthm.2025.12.019_bib49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijcard.2017.06.005","article-title":"Divergent antiarrhythmic effects of resveratrol and piceatannol in a whole-heart model of long QT syndrome","volume":"243","author":"Ellermann","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0378-4274(01)00510-0","article-title":"Cardiotoxicity of new antihistamines and cisapride","volume":"127","author":"Paakkari","year":"2002","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.hrthm.2025.12.019_bib51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00004714-200006000-00005","article-title":"Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome","volume":"20","author":"Flockhart","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/clpt.1987.117","article-title":"Effect kinetics of N-acetylprocainamide-induced QT interval prolongation","volume":"42","author":"Piergies","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib53","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/clpt.1988.181","article-title":"Trimethoprim alters the disposition of procainamide and N-acetylprocainamide","volume":"44","author":"Kosoglou","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib54","first-page":"147","article-title":"Long QT syndrome caused by N-acetyl procainamide in a patient on hemodialysis","volume":"11","author":"Ashida","year":"2015","journal-title":"J Cardiol Cases"},{"key":"10.1016\/j.hrthm.2025.12.019_bib55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1540-8159.1985.tb05854.x","article-title":"Torsades de pointes due to n-acetylprocainamide","volume":"8","author":"Stevenson","year":"1985","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib56","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bcp.15569","article-title":"Cardiovascular concentration-effect relationships of amodiaquine and its metabolite desethylamodiaquine: clinical and preclinical studies","volume":"89","author":"Chan","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(03)02180-0","article-title":"Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk","volume":"477","author":"Lacroix","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/11319400-000000000-00000","article-title":"Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study","volume":"30","author":"Rosignoli","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.hrthm.2025.12.019_bib59","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/AAC.01115-10","article-title":"Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria","volume":"55","author":"Djimd\u00e9","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.hrthm.2025.12.019_bib60","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cpt.1716","article-title":"Safety, pharmacokinetics, and mosquito-lethal effects of ivermectin in combination with dihydroartemisinin-piperaquine and primaquine in healthy adult Thai subjects","volume":"107","author":"Kobylinski","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1220796","article-title":"Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive in vitro proarrhythmia assay (CiPA)","volume":"14","author":"Yoon","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib62","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/cid\/ciac252","article-title":"Pharmacokinetics and safety of bedaquiline in human immunodeficiency virus (HIV)-positive and negative older children and adolescents with rifampicin-resistant tuberculosis","volume":"75","author":"Hughes","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hrthm.2025.12.019_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac372","article-title":"Model-predicted impact of ECG monitoring strategies during bedaquiline treatment","volume":"9","author":"van Beek","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.hrthm.2025.12.019_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107460","article-title":"Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients","volume":"65","author":"Vongjarudech","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.hrthm.2025.12.019_bib65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/taap.2002.9383","article-title":"In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone","volume":"180","author":"Titier","year":"2002","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib66","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1177\/02698811211003477","article-title":"Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age","volume":"35","author":"Hommers","year":"2021","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib67","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/sj.clpt.6100194","article-title":"Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses","volume":"82","author":"Salih","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib68","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.clpt.6100195","article-title":"Factors affecting drug concentrations and QT interval during thioridazine therapy","volume":"82","author":"Thanacoody","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib69","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Swainston Harrison","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.hrthm.2025.12.019_bib70","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/00007691-200310000-00010","article-title":"Routine therapeutic drug monitoring in patients treated with 10-360 mg\/day citalopram","volume":"25","author":"Le Bloc'h","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.hrthm.2025.12.019_bib71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF03160963","article-title":"Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest","volume":"4","author":"Tarabar","year":"2008","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib72","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/FJC.0b013e318030aff7","article-title":"QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study","volume":"49","author":"Zhang","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/phar.2498","article-title":"Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program","volume":"41","author":"Titus-Lay","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.hrthm.2025.12.019_bib74","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40291-015-0137-4","article-title":"A possible mechanistic link between the CYP2C19 genotype, the methadone metabolite ethylidene-1,5-dimethyl-3,3-Diphenylpyrrolidene (EDDP), and methadone-induced corrected QT interval prolongation in a pilot study","volume":"19","author":"Carlquist","year":"2015","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.284","article-title":"Characterizing QT interval prolongation in early clinical development: a case study with methadone","volume":"5","author":"Dubois","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.hrthm.2025.12.019_bib76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(02)02700-0","article-title":"Interactions of the narcotic l-alpha-acetylmethadol with human cardiac K+ channels","volume":"458","author":"Kang","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib77","first-page":"985.e5-6","article-title":"Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels","volume":"33","author":"O\u2019Connell","year":"2015","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.hrthm.2025.12.019_bib78","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/15563650.2016.1138226","article-title":"How toxic is ibogaine?","volume":"54","author":"Litjens","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.hrthm.2025.12.019_bib79","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12012-016-9366-y","article-title":"Anti-addiction drug ibogaine prolongs the action potential in human induced pluripotent stem cell-derived cardiomyocytes","volume":"17","author":"Rubi","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106620","article-title":"IUPHAR - invited review - Ibogaine \u2013 a legacy within the current renaissance of psychedelic therapy","volume":"190","author":"Mash","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.hrthm.2025.12.019_bib81","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/02698811241237873","article-title":"The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients","volume":"38","author":"Knuijver","year":"2024","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib82","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"Deremer","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib83","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00280-020-04204-y","article-title":"Concentration-QTc analysis of quizartinib in patients with relapsed\/refractory acute myeloid leukemia","volume":"87","author":"Kang","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib84","article-title":"Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia","volume":"17","author":"Vaddady","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.hrthm.2025.12.019_bib85","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/psp4.12724","article-title":"Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors","volume":"11","author":"Krishnatry","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib86","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-012-1916-9","article-title":"Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer","volume":"70","author":"Tolcher","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib87","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/cts.13573","article-title":"Abemaciclib does not increase the corrected QT interval in healthy participants","volume":"16","author":"Chappell","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.hrthm.2025.12.019_bib88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2125.2011.03931.x","article-title":"The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses","volume":"72","author":"Ring","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib89","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/DDDT.S75565","article-title":"A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist","volume":"9","author":"Hoch","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib90","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/bdd.690","article-title":"Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate","volume":"31","author":"Yin","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.hrthm.2025.12.019_bib91","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.clinthera.2012.08.001","article-title":"Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers","volume":"34","author":"Kori","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib92","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/11536300-000000000-00000","article-title":"Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study","volume":"30","author":"Walfridsson","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.hrthm.2025.12.019_bib93","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/ALN.0000000000003103","article-title":"Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: Part I. Pharmacokinetics and clinical pharmacodynamics","volume":"132","author":"Sch\u00fcttler","year":"2020","journal-title":"Anesthesiology"},{"key":"10.1016\/j.hrthm.2025.12.019_bib94","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/cts.13512","article-title":"A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia","volume":"16","author":"Tsukada","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.hrthm.2025.12.019_bib95","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s10928-024-09948-1","article-title":"No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria","volume":"52","author":"Gao","year":"2025","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.hrthm.2025.12.019_bib96","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70218","article-title":"Clinical evaluation of the effect of aficamten on QT\/QTc interval in healthy participants","volume":"18","author":"Maharao","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.hrthm.2025.12.019_bib97","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70139","article-title":"Effect of a supratherapeutic dose of omaveloxolone on the corrected QT interval in healthy participants: a randomized, double-blind, placebo- and active-controlled, three-way crossover study","volume":"18","author":"Zahir","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.hrthm.2025.12.019_bib98","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.taap.2003.11.009","article-title":"Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration","volume":"195","author":"Trachsel","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib99","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40261-012-0032-2","article-title":"Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions","volume":"33","author":"Mart\u00ednez-Sell\u00e9s","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.hrthm.2025.12.019_bib100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40261-015-0311-9","article-title":"Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers","volume":"35","author":"Gelotte","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.hrthm.2025.12.019_bib101","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.clinthera.2021.09.001","volume":"43","author":"Cella","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib102","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/BF03261901","article-title":"Paliperidone: a review of clinical trial data and clinical implications","volume":"32","author":"Wang","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.hrthm.2025.12.019_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103652","article-title":"Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation","volume":"392","author":"Kaneko","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib104","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1208\/s12248-018-0244-3","article-title":"Virtual thorough QT (TQT) trial-extrapolation of in vitro cardiac safety data to in vivo situation using multi-scale physiologically based ventricular cell-wall model exemplified with tolterodine and fesoterodine","volume":"20","author":"Patel","year":"2018","journal-title":"AAPS J"},{"key":"10.1016\/j.hrthm.2025.12.019_bib105","article-title":"Pharmacometabolomic approach to predict QT prolongation in guinea pigs","volume":"8","author":"Park","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.hrthm.2025.12.019_bib107","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/psp4.12722","article-title":"Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis","volume":"10","author":"Tanneau","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib111","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/FTD.0b013e31803d39f7","article-title":"Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers","volume":"29","author":"Omoruyi","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.hrthm.2025.12.019_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174647","article-title":"Pharmacogenomics study on cadherin 2 network with regard to HIV infection and methadone treatment outcome","volume":"12","author":"Kuo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.hrthm.2025.12.019_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102626","article-title":"A review regarding the article \u2018electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: a systematic review and meta-analysis.\u2019","volume":"49","author":"Li","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib114","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3565(24)35326-1","article-title":"Effects of the T-type Ca(2+) channel blocker mibefradil on repolarization of guinea pig, rabbit, dog, monkey, and human cardiac tissue","volume":"292","author":"B\u00e9nardeau","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ijnp\/pyab085","article-title":"Psilocybin therapy of psychiatric disorders is not hampered by hERG potassium channel-mediated cardiotoxicity","volume":"25","author":"Hackl","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib116","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/FJC.0000000000001449","article-title":"Prolonged exposure to remdesivir inhibits the human ether-a-go-go-related gene potassium current","volume":"82","author":"Amarh","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrthm.2025.12.019_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112684","article-title":"A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women","volume":"148","author":"Dr\u00f6gem\u00f6ller","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.hrthm.2025.12.019_bib118","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cpt.3047","article-title":"ICH S7B in vitro assays do not address mechanisms of QTC prolongation for peptides and proteins - data in support of not needing dedicated QTC studies","volume":"114","author":"Wu","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2025.12.019_bib119","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.drudis.2021.10.009","article-title":"Drug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management","volume":"27","author":"Li","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.hrthm.2025.12.019_bib120","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/CIRCULATIONAHA.123.063917","article-title":"CAVIN1-mediated hERG dynamics: A novel mechanism underlying the interindividual variability in drug-induced long QT","volume":"150","author":"Al Sayed","year":"2024","journal-title":"Circulation"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527125031571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527125031571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:40:43Z","timestamp":1782722443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527125031571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1547527125031571"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2025.12.019","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolite-centric perspectives on QT prolongation: Molecular mechanisms and clinical implications beyond the parent drug","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2025.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}